Kanada - angličtina - Health Canada

matheson gas products canada inc. - carbon dioxide - gas - 100% - carbon dioxide 100% - miscellaneous therapeutic agents

Kanada - angličtina - Health Canada

air liquide canada inc. - carbon dioxide - gas - 100% - carbon dioxide 100% - other miscellaneous therapeutic agents

Kanada - angličtina - Health Canada

linde canada inc. - carbon dioxide - gas - 99% - carbon dioxide 99% - other miscellaneous therapeutic agents

Kanada - angličtina - Health Canada

messer canada inc. - carbon dioxide - gas - 99% - carbon dioxide 99% - other miscellaneous therapeutic agents

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

linde sverige ab - carbon 0,28 %; helium 9,3 % - medicinal gas, compressed - carbon monoxide 0.28 %; helium 9.3 % - other diagnostic agents

Izrael - angličtina - Ministry of Health

rekah pharmaceutical industry ltd, israel - sodium bicarbonate - tablets - sodium bicarbonate 500 mg - sodium bicarbonate - sodium bicarbonate - antacid.

Evropská unie - angličtina - EMA (European Medicines Agency)

sanofi b.v. - sevelamer carbonate - hyperphosphatemia; renal dialysis - all other therapeutic products - sevelamer carbonate winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.sevelamer carbonate winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.sevelamer carbonate winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Spojené státy - angličtina - NLM (National Library of Medicine)

onpharma, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 84 mg in 1 ml - sodium bicarbonate inj., 8.4% usp neutralizing additive solution is indicated to hasten onset of analgesia and reduce injection pain, by adjusting commercial preparations of lidocaine w/ epinephrine anesthetic solution to a more physiologic ph. not for use as a systemic alkalizer. barash pg, cullen bf, stoelting rk, clinical anesthesia (4th ed. 2001 lippincott williams and wilken). bhatt h, powell kj, jean da, first aid for the anesthesiology boards, an insider's guide (2011, mcgraw-hill medical). cepeda ms, tzortzopoulou a, thackrey m, hudcova j, arora gandhi p, schumann r., adjusting the ph of lidocaine for reducing pain on injection. cochrane database of systematic reviews 2010, issue 12. art. no.: cd006581. chu lf, clinical anesthesiology board review(2005, mcgraw-hill medical). malamed sf,handbook of local anesthesiology(5th ed. 2004, elsevier mosby). miller rd, miller's anesthesia (6th ed. 2004). stoelting rk, miller rd,basics of anesthesia(5th ed. 2007, churchill livingstone el

Spojené státy - angličtina - NLM (National Library of Medicine)

remedyrepack inc. - sevelamer carbonate (unii: 9ycx42i8iu) (sevelamer - unii:941n5duu5c) - sevelamer carbonate 800 mg - sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults with chronic kidney disease (ckd) on dialysis. pediatric use information is approved for genzyme corporation’s renvela (sevelamer carbonate) tablets and renvela (sevelamer carbonate) for oral suspension. however, due to genzyme corporation’s marketing exclusivity rights, these drug products are not labeled with that pediatric information. sevelamer carbonate tablets are contraindicated in patients with bowel obstruction. sevelamer carbonate tablets are contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients. risk summary sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see clinical pharmacology

Spojené státy - angličtina - NLM (National Library of Medicine)

american health packaging - sevelamer carbonate (unii: 9ycx42i8iu) (sevelamer - unii:941n5duu5c) - sevelamer carbonate 800 mg - sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (ckd) on dialysis. sevelamer carbonate tablets are contraindicated in patients with bowel obstruction. sevelamer carbonate tablets are contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients. risk summary sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see clinical pharmacology (12.2)]. consider supplementation. data animal data in pregnant rats given dietary doses of 0.5, 1.5 or 4.5 g/kg/day of sevelamer hydrochloride during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption